INTERPACE BIOSCIENCES INC (IDXG) earnings
IDXG earnings moved a median of +2.21% by the close. Quarterly and annual IDXG reports and results, each read against the price at its own news timestamp. Back to the IDXG overview →
25 measured IDXG earnings events.
Where these IDXG earnings landedvs 23 measured IDXG earnings reactions
| Middle 50% of IDXG earnings reactions | -4.23% to +2.84% |
|---|---|
| Median reaction (to close) | +2.21% |
| Measured reactions | 23 |
Point-in-time · zero look-ahead
Half of the 23 IDXG earnings events with a measured close landed between -4.23% and +2.84%; 52% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Interpace Biosciences Announces Preliminary Unaudited Third Quarter 2026 Revenue | Press release | +0.00% | -2.04% | |
| Form 10-Q INTERPACE BIOSCIENCES, For: Mar 31 | SEC filing · Form 10-Q | -1.37% | -7.32% | |
| Interpace Biosciences Announces First Quarter 2026 Financial and Business Results | Press release | -1.37% | -7.32% | |
| Form 10-K/A INTERPACE BIOSCIENCES, For: Dec 31 | SEC filing · Form 10-K | +3.50% | +6.00% | |
| Form 10-K INTERPACE BIOSCIENCES, For: Dec 31 | SEC filing · Form 10-K | +1.71% | +8.00% | |
| Form 10-Q INTERPACE BIOSCIENCES, For: Sep 30 | SEC filing · Form 10-Q | -4.67% | — | |
| Interpace Biosciences Announces Third Quarter 2025 Financial and Business Results | Press release | -4.67% | — | |
| Form 10-Q INTERPACE BIOSCIENCES, For: Jun 30 | SEC filing · Form 10-Q | +0.00% | +2.41% | |
| Interpace Biosciences Announces Second Quarter 2025 Financial and Business Results | Press release | +0.00% | +2.41% | |
| Form 10-Q INTERPACE BIOSCIENCES, For: Mar 31 | SEC filing · Form 10-Q | -0.46% | -1.32% | |
| Interpace Biosciences Announces First Quarter 2025 Financial and Business Results | Press release | -0.46% | -1.32% | |
| Form 10-K/A INTERPACE BIOSCIENCES, For: Dec 31 | SEC filing · Form 10-K | +0.00% | -10.34% | |
| Form 10-K INTERPACE BIOSCIENCES, For: Dec 31 | SEC filing · Form 10-K | +0.00% | -2.15% | |
| Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results | Press release | +4.28% | -6.31% | |
| Form 10-Q INTERPACE BIOSCIENCES, For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -8.59% | |
| Interpace Biosciences Announces Record Third Quarter 2024 Financial and Business Results | Press release | +8.43% | +20.08% | |
| Form 10-Q INTERPACE BIOSCIENCES, For: Jun 30 | SEC filing · Form 10-Q | +0.00% | +21.37% | |
| Interpace Biosciences Announces Record Second Quarter 2024 Financial and Business Results | Press release | +0.00% | -18.24% | |
| Form 10-Q INTERPACE BIOSCIENCES, For: Mar 31 | SEC filing · Form 10-Q | -8.51% | +2.84% | |
| Interpace Biosciences Announces First Quarter 2024 Financial and Business Results | Press release | -8.51% | +2.84% | |
| Form 10-K/A INTERPACE BIOSCIENCES, For: Dec 31 | SEC filing · Form 10-K | +0.00% | +2.21% | |
| Form 10-K INTERPACE BIOSCIENCES, For: Dec 31 | SEC filing · Form 10-K | +0.00% | +2.74% | |
| Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results | Press release | +25.00% | +38.33% | |
| Form 10-Q INTERPACE BIOSCIENCES, For: Sep 30 | SEC filing · Form 10-Q | +6.84% | +2.56% | |
| Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results | Press release | +0.00% | -0.87% |
Keep exploring
More IDXG: analyst actions → · SEC filings → · IDXG overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| VIVOS INC (RDGL) | 88 | 0.00% | 43% |
| AMBU A S UNSP/ADR (AMBBY) | 87 | 0.00% | 13% |
| Organovo Holdings, Inc. (ONVO) | 87 | -0.95% | 37% |
| Flurotech Ltd (TEST_CDNX) | 87 | 0.00% | 41% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.